Natco Pharma Limited has launched Brivaracetam tablets under brand Brecita in the domestic market.
Brivaracetam is for the treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under the brand name Briviact.
Hyderabad-based Natco’s Brecita tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of ₹25 and ₹35 per tablet respectively, according to a release.
Epilepsy patients in India are estimated to be between 5-10 million.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.